Case report shows concurrent infections in a patient with bullous pemphigoid on glucocorticoids, indicating infection risk.
Glucocorticoids exert their therapeutic effects by broadly suppressing the activity of immune cells, thereby increasing the risk of infection. Although this risk is dose-dependent, a clinically meaningful increase in infection risk persists even at daily doses lower than 5 mg of prednisone equivalent. We herein report the first documented case of a patient who developed concurrent crusted scabies and Candida albicans infection following glucocorticoid therapy for bullous pemphigoid.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: